Vaccination Strategies Against Highly Variable Pathogens
Download Vaccination Strategies Against Highly Variable Pathogens PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get Vaccination Strategies Against Highly Variable Pathogens book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages.
Vaccination Strategies Against Highly Variable Pathogens
Vaccines against antigenically stable pathogens, or pathogens that only exist in a limited number of serotypes, have been very successful in the past and have drastically decreased the incidence and lethality of many diseases. However, when it comes to highly variable pathogens or viruses that exist in multiple serotypes, the traditional methods for vaccine development have reached their limits. This volume highlights the development of vaccines against such challenging pathogens. Novel approaches for immunogen design, including structure-guided vaccine development and vaccines targeting glycans, as well as adjuvants and animal models used for testing possible vaccine candidates are outlined and discussed in detail. Given its scope, the book will appeal to scientists in the fields of infectious diseases, microbiology and medicine.
Anticandidal Therapeutics
Developments of antifungal agents have declined as compared to other antibiotics that have displayed a potent development with time. There is an urgent need for both prophylactic and therapeutic treatments worldwide to control the severity of infections caused by Candida. Anticandidal Therapeutics: Discovery and Development provides the readers with a compiled knowledge of the fungal human infection Candida and the development of anticandidal drugs. Anticandidal Therapeutics helps researchers form the basis for the discovery and development of novel anticandidal therapies. In 14 chapters this book provides collective information on anticandidal agents and their discovery and development with respect to major drug transporter families, different stages of anticandidal agent development, recent trends and progress in antifungal translational research, clinical studies status of anticandidal therapeutic agents, and drug repurposing for development of novel anticandidal agents. - Highlights the mechanistic actions of some therapeutic agents against Candida - Focuses on anticandidal agents rather than general antifungal agents - Discusses the stage of development of new antifungal drugs, the repositioning of drugs, and how this could help in treatment
Immunity to Malaria and Vaccine Strategies
Author: Kevin N. Couper
language: en
Publisher: Frontiers Media SA
Release Date: 2019-10-10
Malaria, caused by infection with protozoan parasites belonging to the genus Plasmodium, is a highly prevalent and lethal infectious disease, responsible for 435,000 deaths in 2017. Optimism that malaria was gradually being controlled and eliminated has been tempered by recent evidence that malaria control measures are beginning to stall and that Plasmodium parasites are developing resistance to front-line anti-malarial drugs. An important milestone has been the recent development of a malaria vaccine (Mosquirix) for use in humans, the very first against a parasitic infection. Unfortunately, this vaccine has modest and short-lived efficacy, with vaccinated individuals possibly being at increased risk of severe malarial disease when protection wanes. Thus, to define new ways to combat malaria, there remains an urgent requirement to identify the immune mechanisms that promote resistance to malarial disease and to understand why these so often fail. The review and primary research articles in this Research Topic illustrate the breadth of research performed worldwide aimed to understand the biology of the Plasmodium parasite, the roles of the various cell types that act within the immune response against the parasite, and the parasitological and immunological basis of severe malarial disease. The articles in section 1 exemplify the different vaccination strategies being developed and tested by the research community in the fight against malaria. The articles in section 2 review important overarching aspects of malaria immunology and the use of models to study human malaria. The articles in section 3 describe the ways through which the Plasmodium parasite is initially recognised by the immune system during infection, how the parasite can directly impact this critical event to restrict anti-Plasmodial immunity, and resolve the roles of key innate cell populations, such as dendritic cells, in coordinating malarial immunity. The articles in sections 4-6 outline the roles T and B cell populations play during malaria, highlighting the activation, diversification and regulation of the crucial cell types during malaria, and discuss some of the reasons adaptive immunity to malaria is often considered so poor compared with other diseases. The articles in section 7 provide up to date information on the pathogenesis of cerebral malaria, bridging our understanding of the syndrome in humans with information learned from animal models. Overall, the articles in this research, many of which are published by leaders in the malaria field, emphasize the imagination and technical advances being employed by researchers against malaria. We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS). We hereby state publicly that the IUIS has had no editorial input in articles included in this Research Topic, thus ensuring that all aspects of this Research Topic are evaluated objectively, unbiased by any specific policy or opinion of the IUIS.